Open AccessOutbreak control management: Lessons from SARS‐CoV‐2 infections in 2020–2022 in Hong Kong, an international municipality with high‐frequency travelers
Author(s) -
Feng Yaxiu,
Young Ching Han,
Lau Siu Hin,
He MingLiang
Publication year - 2022
Publication title -
medcomm
Language(s) - English
Resource type - Journals
ISSN - 2688-2663
DOI - 10.1002/mco2.158
Subject(s) - outbreak , infection control , transmission (telecommunications) , medicine , vaccination , covid-19 , government (linguistics) , environmental health , population , attack rate , mortality rate , virology , infectious disease (medical specialty) , intensive care medicine , disease , linguistics , philosophy , electrical engineering , engineering
Abstract The control management of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infections is one of the most challenges in the 21st century. By May 8th, 2022, SARS‐CoV‐2 has infected over 510 million people with 6.2 million death worldwide and over 1.2 million people with 9133 deaths in the fifth wave of infection in Hong Kong. The government responded rapidly in the early days of the 2020 outbreak, and the results were encouraging to control COVID‐19 outbreak unavailable of vaccine. The quick responses to the epidemic alerts, for example, public education and control policies, kept residents safe from infection in the city with such a high population density and large‐scale travelers. Nevertheless, the extremely high infectivity, Omicron variant infections, and the shortcomings of transmission control measures led to uncontrollable outbreak in 2022. The weak immunity groups, elderly and children, experienced a high hospitalization rate and mortality rate because of low vaccination rate. Currently, the infection is under well controlled. This study timely summarizes the challenges, policy, and lessons of SARS‐CoV‐2 outbreak control from 2020 to 2022. More importantly, the lesson and policy revealed from this study may be beneficial and applied to other cities with the outbreak of highly infectious SARS‐CoV‐2.